REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis

Authors
Category Primary study
ConferenceAnnals of Oncology
Year 2018
This article has no abstract
Epistemonikos ID: 5984c3a414b18fc8d84113066ac7915dc0a4e3ab
First added on: Feb 01, 2023